{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-129488","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.390233+00:00","generated_at":"2026-05-20T09:36:02.751452+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B","bullets":["€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.","Net proceeds fund tender offer for up to $2.25B (upsized from $2B) and repay other outstanding debt.","Notes are senior unsecured obligations guaranteed by Teva; customary covenants and events of default.","Issuance made under Teva's existing shelf registration statement filed February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-129488","json":"https://secwatch.observer/filing/0001193125-25-129488.json","markdown":"https://secwatch.observer/filing/0001193125-25-129488.md","text":"https://secwatch.observer/filing/0001193125-25-129488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/d918164d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T09:36:02.751452+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18e93cd4267bb364a34eeb3b3bd062f19ae13730","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of €1,000,000,000 with The Bank of New York Mellon, as trustee at 4.125% maturing June 1, 2031.","evidence_excerpt":"On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"€1,000,000,000"},{"label":"Counterparty","value":"The Bank of New York Mellon, as trustee"},{"label":"Rate","value":"4.125%"},{"label":"Maturity","value":"June 1, 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9174af004239d30a54cd4a2cafa50abb4a095d2d","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD incurred senior notes of $500,000,000 with The Bank of New York Mellon, as trustee at 6.000% maturing December 1, 2032.","evidence_excerpt":"On May 28, 2025, (i) Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”), a wholly owned subsidiary of Teva Pharmaceutical Industries Limited (the “ Company ”), issued €1,000,000,000 aggregate principal amount of 4.125% Senior Notes due 2031 (the “ Euro Notes ”); (ii) Teva Pharmaceutical Finance Netherlands III B.V. (“ Teva Finance III ”), a wholly owned subsidiary of the Company, issued $500,000,000 aggregate principal amount of 6.000% Senior Notes due 2032 (the “ 2032 USD Notes ”); and (iii) Teva Pharmaceutical Finance Netherlands IV B.V. (“ Teva Finance IV ” and, together with Teva Finance II and Teva Finance III, the “ Issuers ”), a wholly owned subsidiary of the Company, issued $700,000,0000 aggregate principal amount of 5.750% Senior Notes due 2030 (the “ 2030 USD Notes ” and, together with 2030 USD Notes, the “ USD Notes ” and together with the Euro Notes, the “ Notes ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/0001193125-25-129488-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$500,000,000"},{"label":"Counterparty","value":"The Bank of New York Mellon, as trustee"},{"label":"Rate","value":"6.000%"},{"label":"Maturity","value":"December 1, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}